Social Media Drives Loniten Shortages for Alopecia Treatment

November 12, 2026 Dr. Michael Lee – Health Editor Health

At least 30% of the population in Gipuzkoa suffers from hypertension, while social media videos drive a parallel shortage of the severe hypertension drug Loniten for alopecia treatment.

Key Clinical Takeaways:

  • Loniten, prescribed primarily for severe high blood pressure, has faced shortages in pharmacies following viral social media claims regarding hair loss.
  • Pfizer anticipates that supply issues for the medication will resolve by December 15, according to information from the Agencia Española del Medicamento y Productos Sanitarios (Aemps).
  • The active ingredient, minoxidil, acts as a peripheral vasodilator that increases blood flow to hair follicles while carrying cardiovascular side effects.

The 1970s vasodilator behind modern cosmetic demand

The active ingredient in Loniten is minoxidil, discovered originally in the 1970s as a potent drug to combat arterial hypertension. Patients began developing hair as an involuntary side effect due to its vasodilating mechanism, which expands peripheral blood vessels and increases the flow of blood, oxygen, and nutrients directly to hair follicles.

According to the product insert, side effects can include rapid heartbeat or tachycardia, inflammation of the outer membrane covering the heart or pericarditis, excessive body hair growth known as hypertrichosis, hair color changes, or electrocardiogram alterations. High blood pressure itself remains the most frequent chronic disease, with an estimated prevalence in people over 18 of 21-37% for women and 34-50% for men in Euskadi.

Controlled distribution across Gipuzkoa pharmacies

At least 215,000 people in Gipuzkoa live with hypertension, and the territory has noted the lack of supply in pharmacies. The Colegio Oficial de Farmacéuticos de Gipuzkoa (COFG) confirms the shortage is registered with Aemps, and some offices reported difficulties through the Centro de Información sobre el Suministro de Medicamentos (Cismed).

However, the organization specifies it has received no direct queries on the matter and that it does not currently cause major incidents in the territory. The COFG underlines that distribution of the medication is controlled to serve authorized indications for patients with severe hypertension who do not respond to other treatments, while two lower-dose presentations of the same active ingredient are not listed as out of stock.

The Aemps contacted Pfizer, the marketing laboratory, which implemented a controlled distribution due to limited units. Pfizer expects supply issues to end on December 15, according to Aemps sources.

Parallels with the 2022 Ozempic shortage

The situation with Loniten echoes the 2022 episode involving Ozempic, a medication containing semaglutide that gained notoriety for weight loss alongside its authorized indication for type 2 diabetes. That popularity coincided with supply problems that prompted health authorities to warn of difficulties for patients needing the treatment to control diabetes.

The Agencia Española de Medicamentos y Productos Sanitarios urged prioritized use for authorized diabetes indications during the Ozempic shortages.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this